Sustained release system of paclitaxel based on composite nanofibers for inhibiting renal clear cell carcinoma
Source abstract
Abstract
Abstract The recurrence and metastasis of renal cell carcinoma aresevere challenges in clinical treatment. At present, it is urgent to find a strategy to solve this problem and improve the therapeutic effect. In this study, we designed a programmed release system of anticancer drugs by preparing a nanofiber system with two kinds of diameters and biomaterials (polylactic acid-glycolic acid (PLGA) and silk protein) as drug carriers (paclitaxel), which inspired the occurrence and pathological microenvironment of renal cell carcinoma. The controlled degradation of PLGA nanofibers as a drug carrier achieved the short-term release of paclitaxel, which could rapidly inhibit the spread and metastasis of renal cancer, while the silk protein nanofibers as a drug carrier with slow degradation could provide the long time and continuous release of paclitaxel to prevent the proliferation of renal cancer cells and inhibit recurrence. The synergistic effect of the sustained release system of paclitaxel successfully achieved inhibition of the recurrence and metastasis of renal cell carcinoma and improve the therapeutic effect of renal cell carcinoma. The paclitaxel release profile showed that the PLGA nanofiber drug system provided controlled release of paclitaxel in the first 14 days, while the silk protein nanofiber system provided a relatively stable and long-duration release of paclitaxel (1 month). In vitro experiments showed that the sustained release system of paclitaxel had a lasting inhibitory effect on the proliferation of renal clear cell carcinoma cells. These results indicated that the sustained release system of paclitaxel could be used as a promising drug delivery system with highly efficient implementations to reduce the frequency of systemic administration and inhibit tumor growth and recurrence, which could provide a new strategy for the clinical applications in renal cell carcinoma microenvironment.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Renal cell carcinoma treatment · Renal and related cancers · Tissue Engineering and Regenerative Medicine
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (48)
Show source-provided references
1. Bray F, Laversanne M, Weiderpass E, Soerjomataram I (2021) The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer 127(16):3029–303010.1002/cncr.33587 ↗
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–24910.3322/caac.21660 ↗
3. Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics 2021. CA Cancer J Clin 71(1):7–3310.3322/caac.21654 ↗
4. Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V (2017) Renal cell carcinoma. Nat Rev Dis Primers 3:1700910.1038/nrdp.2017.9 ↗
5. Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, Rawla P, Barsouk A (2020) Epidemiology of renal cell carcinoma. World J Oncol 11(3):79–8710.14740/wjon1279 ↗
6. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–92410.1016/j.eururo.2015.01.005 ↗
7. Motzer RJ, Hutson TE, Mccann L, Deen K, Choueiri TK (2014) Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 370(18):1769–177010.1056/NEJMc1400731 ↗
8. Motzer R, Alekseev B, Rha S-Y, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong S-H, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 384(14):1289–130010.1056/NEJMoa2035716 ↗
9. Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384(9):829–84110.1056/NEJMoa2026982 ↗
10. Zhu L, Chen L (2019) Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett 24:4010.1186/s11658-019-0164-y ↗
11. Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodríguez-Abreu D, Hussein M, Soo R, Conter HJ, Kozuki T, Huang K-C, Graupner V, Sun SW, Hoang T, Jessop H, Mccleland M, Ballinger M, Sandler A, Socinski MA (2020) Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. J Thorac Oncol 15(8):1351–136010.1016/j.jtho.2020.03.028 ↗
12. Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, Elsahwi K, Celano P, Bellone S, Azodi M, Litkouhi B et al (2020) Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin–paclitaxel–trastuzumab in advanced (stage III–IV) or recurrent uterine serous carcinomas that overexpress her2/neu (NCT01367002): updated overall survival analysis. Clin Cancer Res 26(15):392810.1158/1078-0432.CCR-20-0953 ↗
13. Weaver BA (2014) How taxol/paclitaxel kills cancer cells. Mol Biol Cell 25(18):2677–268110.1091/mbc.e14-04-0916 ↗
14. Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82(15):1247–125910.1093/jnci/82.15.1247 ↗
15. Rahnfeld L, Luciani P (2020) Injectable lipid-based depot formulations: where do we stand? Pharmaceutics 12(6):56710.3390/pharmaceutics12060567 ↗
16. Lee JH, Moon M, Kim Y-C, Chung SJ, Oh J, Kang DY, Lee S-Y, Lee K-H, Yun J, Kang H-R (2020) A one-bag rapid desensitization protocol for paclitaxel hypersensitivity:a noninferior alternative to a multi-bag rapid desensitization protocol. J Allergy Clin Immunol Pract 8(2):696–70310.1016/j.jaip.2019.10.014 ↗
17. Feldweg AM, Lee C-W, Matulonis UA, Castells M (2005) Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 96(3):824–910.1016/j.ygyno.2004.11.043 ↗
18. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S (2009) Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomed 4:9910.1504/IJNM.2009.028116 ↗
19. Namgung R, Mi Lee Y, Kim J, Jang Y, Lee B-H, Kim I-S, Sokkar P, Rhee YM, Hoffman AS, Kim WJ (2014) Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy. Nat Commun 5:370210.1038/ncomms4702 ↗
20. Niiyama E, Uto K, Lee CM, Sakura K, Ebara M (2019) Hyperthermia nanofiber platform synergized by sustained release of paclitaxel to improve antitumor efficiency. Adv Healthc Mater 8(13):e190010210.1002/adhm.201900102 ↗
21. Li Z, Zhang X, Guo Z, Shi L, Jin L, Zhu L, Cai X, Zhang J, Zhang YS, Li J (2021) Nature-derived bionanomaterials for sustained release of 5-fluorouracil to inhibit subconjunctival fibrosis. Mater Today Adv 11:10015010.1016/j.mtadv.2021.100150 ↗
22. Chen Y, Shen W, Tang C, Huang J, Fan C, Yin Z, Hu Y, Chen W, Ouyang H, Zhou Y, Mao Z, Chen X (2020) Targeted pathological collagen delivery of sustained-release rapamycin to prevent heterotopic ossification. Sci Adv 6(18):eaay952610.1126/sciadv.aay9526 ↗
23. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V (2012) PLGA-based nanoparticles: an overview of biomedical applications. J Control Release Off J Control Release Soc 161(2):505–52210.1016/j.jconrel.2012.01.043 ↗
24. Acharya S, Sahoo SK (2011) PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 63(3):170–18310.1016/j.addr.2010.10.008 ↗
25. Vert M, Mauduit J, Li S (1994) Biodegradation of PLA/GA polymers: increasing complexity. Biomaterials 15(15):1209–121310.1016/0142-9612(94)90271-2 ↗
26. Huang W, Ling S, Li C, Omenetto FG, Kaplan DL (2018) Silkworm silk-based materials and devices generated using bio-nanotechnology. Chem Soc Rev 47(17):6486–650410.1039/C8CS00187A ↗
27. Wang Z, Yang Z, Jiang J, Shi Z, Mao Y, Qin N, Tao TH (2021) Silk microneedle patch capable of on-demand multi-drug delivery to the brain for glioblastoma treatment. Adv Mater Deerfield Beach Fla 34:e210660610.1002/adma.202106606 ↗
28. Chambre L, Martín-Moldes Z, Parker RN, Kaplan DL (2020) Bioengineered elastin- and silk-biomaterials for drug and gene delivery. Adv Drug Deliv Rev 160:186–19810.1016/j.addr.2020.10.008 ↗
29. Han C, Zhou J, Liu B, Liang C, Pan X, Zhang Y, Zhang Y, Wang Y, Shao L, Zhu B, Wang J, Yin Q, Yu X-Y, Li Y (2019) Delivery of miR-675 by stem cell-derived exosomes encapsulated in silk fibroin hydrogel prevents aging-induced vascular dysfunction in mouse hindlimb. Mater Sci Eng C Mater Biol Appl 99:322–33210.1016/j.msec.2019.01.122 ↗
30. Xue J, Wu T, Dai Y, Xia Y (2019) Electrospinning and electrospun nanofibers: methods, materials, and applications. Chem Rev 119(8):5298–541510.1021/acs.chemrev.8b00593 ↗
31. Yang G, Li X, He Y, Ma J, Ni G, Zhou S (2017) From nano to micro to macro: electrospun hierarchically structured polymeric fibers for biomedical applications. Progress Polym ence 81:80–11310.1016/j.progpolymsci.2017.12.003 ↗
32. Qi R-L, Tian X-J, Guo R, Luo Y, Shen M-W, Yu J-Y, Shi X-Y (2016) Controlled release of doxorubicin from electrospun MWCNTs/PLGA hybrid nanofibers. Chin J Polym Sci 34(9):1047–105910.1007/s10118-016-1827-z ↗
33. Wu H, Liu S, Xiao L, Dong X, Lu Q, Kaplan DL (2016) Injectable and pH-responsive silk nanofiber hydrogels for sustained anticancer drug delivery. ACS Appl Mater Interfaces 8(27):17118–1712610.1021/acsami.6b04424 ↗
34. Chen Z, Zhuang Q, Cheng K, Ming Y, Zhao Y, Ye Q, Zhang S (2020) Long non-coding RNA TCL6 enhances preferential toxicity of paclitaxel to renal cell carcinoma cells. J Cancer 11(6):1383–139210.7150/jca.32552 ↗
35. Rausch M, Weiss A, Achkhanian J, Rotari A, Nowak-Sliwinska P (2020) Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma. Br J Cancer 123(4):556–56710.1038/s41416-020-0890-y ↗
36. Chua CYX, Ho J, Demaria S, Ferrari M, Grattoni A (2020) Emerging technologies for local cancer treatment. Adv Ther 3(9):200002710.1002/adtp.202000027 ↗
37. Kesharwani P, Tekade RK, Jain NK (2011) Spectrophotometric estimation of paclitaxel. Int J Adv Pharm Sci 2(1):29–32
38. Pourtalebi Jahromi L, Ghazali M, Ashrafi H, Azadi A (2020) A comparison of models for the analysis of the kinetics of drug release from PLGA-based nanoparticles. Heliyon. 6(2):e0345110.1016/j.heliyon.2020.e03451 ↗
39. Solomun JI, Totten JD, Wongpinyochit T, Florence AJ, Seib FP (2020) Manual versus microfluidic-assisted nanoparticle manufacture: impact of silk fibroin stock on nanoparticle characteristics. ACS Biomater Sci Eng 6(5):2796–280410.1021/acsbiomaterials.0c00202 ↗
40. Yohe ST, Herrera VL, Colson YL, Grinstaff MW (2012) 3D superhydrophobic electrospun meshes as reinforcement materials for sustained local drug delivery against colorectal cancer cells. J Control Release 162(1):92–10110.1016/j.jconrel.2012.05.047 ↗
41. Kim K, Luu YK, Chang C, Fang D, Hsiao BS, Chu B, Hadjiargyrou M (2004) Incorporation and controlled release of a hydrophilic antibiotic using poly(lactide-co-glycolide)-based electrospun nanofibrous scaffolds. J Control Release 98(1):47–5610.1016/j.jconrel.2004.04.009 ↗
42. Laiva AL, Venugopal JR, Karuppuswamy P, Navaneethan B, Gora A, Ramakrishna S (2015) Controlled release of titanocene into the hybrid nanofibrous scaffolds to prevent the proliferation of breast cancer cells. Int J Pharm 483(1):115–12310.1016/j.ijpharm.2015.02.025 ↗
43. Minoura N, Tsukada M, Nagura M (1990) Physico-chemical properties of silk fibroin membrane as a biomaterial. Biomaterials 11(6):430–43410.1016/0142-9612(90)90100-5 ↗
44. Abbasnezhad N, Zirak N, Shirinbayan M, Tcharkhtchi A, Bakir F (2021) On the importance of physical and mechanical properties of PLGA films during drug release. J Drug Deliv Sci Technol 63:10244610.1016/j.jddst.2021.102446 ↗
45. Li S, Yang J, Wang J, Gao W, Ding Y, Ding Y, Jia Z (2018) Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1. Cell Biosci 8(1):910.1186/s13578-018-0209-3 ↗
46. Kakehi Y, Kanamaru H, Yoshida O, Ohkubo H, Nakanishi S, Gottesman MM, Pastan I (1988) Measurement of multidrug-resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J Urol 139(4):862–86510.1016/S0022-5347(17)42663-2 ↗
47. Li Z, Huang J, Wu J (2021) pH-sensitive nanogels for drug delivery in cancer therapy. Biomater Sci 9(3):574–58910.1039/D0BM01729A ↗
48. Tong X, Pan W, Su T, Zhang M, Dong W, Qi X (2020) Recent advances in natural polymer-based drug delivery systems. React Funct Polym 148:10450110.1016/j.reactfunctpolym.2020.104501 ↗